Charlotte-made Italian Ice cools you off and gets you high
Why it matters: While cannabis is increasingly found in a variety of products, from seltzers to baked goods, Concetto's Italian Ice owner Amy Liu says her product offers something different: A discrete and refreshing way to consume THC or CBD — especially on a hot, summer day in North Carolina.
Made in Charlotte, Infused Ice CLT launched about a month ago. You can find them at several stores: Sweet Union Hemp Company in Monroe, Sip City in Plaza Midwood, Tip Top on The Plaza, Old Town Public House in Cornelius and Common Market.
The five-ounce jars retail for around $10 to $12, depending on the store. Flavors so far are cherry, mango and lemon — some of the bestsellers in Liu's store.
How it works: The ices contain 25 milligrams of THC Delta-9 or CBD — a moderate dose for experienced users and a good option for newcomers to split with a friend or save in the freezer for later. It takes about an hour for the effects to kick in.
"I always recommend for new users — just start slow," Liu says.
CBD is known for its calming effects and easing anxiety and pain but it does not make you high.
THC, marijuana's psychoactive component, is the one that will produce the "high" sensation.
Context: Liu opened Concetto's Italian Ice about a year ago, making the transition from her former job as an occupational hand therapist of 18 years.
"I wanted to bring a bit of New York to here," she says."We have a ton of Italian ice stores where I grew up in Queens and Long Island."
Around the same time the store opened, Liu says someone suggested she infuse her Italian ice. She began experimenting with different flavors, testing the potency and sending recipes for testing.
Zoom out: Although North Carolina is one of the few remaining states where marijuana is illegal, it has some of the most lenient regulations for products extracted from hemp.
Liu's product complies with the 2018 Farm Bill, which declassified hemp as a controlled substance so long as it contains less than 0.3% Delta-9 THC. North Carolina updated its laws in 2022 to align with the federal regulation.
Since then, intoxicating products have become increasingly available at North Carolina dispensaries, bars and breweries, bottle shops, and even pizzerias.
State lawmakers are considering newly filed legislation to enact age restrictions, set dosage limits, require licenses for hemp manufacturers and mandate product testing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
3 Asian Penny Stocks With Market Caps Under US$400M
As global markets react to economic data and potential interest rate changes, Asian markets have shown resilience, with key indices like Japan's Nikkei 225 reaching record highs. Amidst this backdrop, the concept of penny stocks—often seen as a relic from past market eras—remains relevant due to their potential for growth at lower price points. These stocks typically represent smaller or newer companies that can offer significant opportunities when backed by strong financials and sound fundamentals. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.00 THB3.95B ★★★★★☆ JBM (Healthcare) (SEHK:2161) HK$3.07 HK$2.5B ★★★★★★ Lever Style (SEHK:1346) HK$1.63 HK$1.01B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.65 HK$2.21B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.625 SGD253.31M ★★★★★☆ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.83 SGD11.14B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.95 THB1.4B ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ Rojana Industrial Park (SET:ROJNA) THB4.64 THB9.37B ★★★★★☆ BRC Asia (SGX:BEC) SGD3.64 SGD998.63M ★★★★★★ Click here to see the full list of 970 stocks from our Asian Penny Stocks screener. Let's explore several standout options from the results in the screener. Hengxin Technology Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Hengxin Technology Ltd. is an investment holding company involved in the research, design, manufacture, development, and sale of integrated antennas and feeder cables for mobile communications both in the People's Republic of China and internationally, with a market cap of HK$1.02 billion. Operations: Hengxin Technology generates revenue from three main segments: Telecommunications Business (CN¥2.10 billion), New Energy and Services Business (CN¥185.97 million), and Integrated Circuits and Digital Technology (CN¥238.35 million). Market Cap: HK$1.02B Hengxin Technology Ltd., with a market cap of HK$1.02 billion, operates across telecommunications, new energy, and integrated circuits sectors. Despite negative earnings growth over the past year and declining profits over five years, the company maintains a satisfactory net debt to equity ratio of 25.8% and covers short-term liabilities with assets of CN¥2.9 billion. Recent strategic expansion into green energy infrastructure through an 800MW/1600MWh storage project in Shandong Province marks a significant milestone for future growth potential. However, frequent board changes may indicate instability; recent appointments include experienced financial professionals to strengthen governance. Click to explore a detailed breakdown of our findings in Hengxin Technology's financial health report. Evaluate Hengxin Technology's historical performance by accessing our past performance report. VPower Group International Holdings Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: VPower Group International Holdings Limited is an investment holding company that designs, integrates, sells, and installs engine-based electricity generation units across Hong Kong, Mainland China, other Asian countries, Latin America, and internationally with a market cap of approximately HK$1.90 billion. Operations: The company's revenue is primarily derived from its System Integration segment, which generated HK$628.55 million, and its Investment, Building and Operating segment, contributing HK$917.56 million. Market Cap: HK$1.9B VPower Group International Holdings, with a market cap of HK$1.90 billion, is navigating financial challenges as it remains unprofitable with losses increasing over the past five years. However, the company has maintained stable weekly volatility and avoided shareholder dilution recently. Its short-term assets exceed both short and long-term liabilities, providing some financial stability despite a high net debt to equity ratio of 127.2%. Recent corporate guidance indicates an expected profit of approximately HK$20 million for H1 2025 due to asset disposals and reduced interest expenses, contrasting with a significant loss in the previous year. Take a closer look at VPower Group International Holdings' potential here in our financial health report. Learn about VPower Group International Holdings' historical performance here. C-MER Medical Holdings Simply Wall St Financial Health Rating: ★★★★★☆ Overview: C-MER Medical Holdings Limited is an investment holding company that offers ophthalmic services under the C-MER Dennis Lam brand in Hong Kong and Mainland China, with a market cap of HK$2.59 billion. Operations: The company generates revenue from its Hong Kong medical business (HK$901.59 million), Mainland China dental operations (HK$464.58 million), and ophthalmic services in Mainland China (HK$546.99 million). Market Cap: HK$2.59B C-MER Medical Holdings, with a market cap of HK$2.59 billion, faces profitability challenges as losses have grown at 16.5% annually over the past five years. Despite this, the company maintains financial stability with short-term assets exceeding liabilities and cash reserves surpassing total debt. Recent strategic moves include a share buyback program aimed at enhancing net asset value per share and earnings per share, signaling confidence in its long-term prospects. Leadership changes see Dr. Lam transitioning to a senior advisor role while Ms. Li Xiaoting assumes CEO duties, potentially ensuring continuity in corporate strategy and operations. Navigate through the intricacies of C-MER Medical Holdings with our comprehensive balance sheet health report here. Review our historical performance report to gain insights into C-MER Medical Holdings' track record. Make It Happen Get an in-depth perspective on all 970 Asian Penny Stocks by using our screener here. Curious About Other Options? AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1085 SEHK:1608 and SEHK:3309. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
an hour ago
- Yahoo
Coty (COTY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Coty (COTY) reported $1.25 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 8.1%. EPS of -$0.05 for the same period compares to -$0.03 a year ago. The reported revenue represents a surprise of +4.07% over the Zacks Consensus Estimate of $1.2 billion. With the consensus EPS estimate being $0.01, the EPS surprise was -600%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Coty performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenues- Prestige: $760.6 million compared to the $721.85 million average estimate based on five analysts. The reported number represents a change of -5.3% year over year. Net Revenues- Consumer Beauty: $491.8 million compared to the $477.45 million average estimate based on five analysts. The reported number represents a change of -12.3% year over year. Adjusted Operating Income (Loss)- Prestige: $74.7 million versus $76.95 million estimated by two analysts on average. Adjusted Operating Income (Loss)- Consumer Beauty: $-7 million compared to the $-1.36 million average estimate based on two analysts. View all Key Company Metrics for Coty here>>> Shares of Coty have returned -2.4% over the past month versus the Zacks S&P 500 composite's +2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Coty (COTY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
an hour ago
- Yahoo
Barclays Lowers Salesforce (CRM) Price Target Ahead of Q2 Earnings Print
Salesforce, Inc. (NYSE:CRM) is one of the On August 18, Barclays analyst Raimo Lenschow lowered the price target on the stock to $316.00 (from $347.00) while maintaining an Overweight rating. According to the firm, Salesforce's Q2 off-cycle software earnings will be another test to see if the sector can find valuation support. Even though channel checks reveal solid end demand and that stock valuation levels are much lower, artificial intelligence uncertainties still remain. An investor poring over the Wall Street Journal, undecided on their next move. Salesforce, Inc. (NYSE:CRM) is a cloud-based CRM company that has gained popularity after it unveiled its AI-powered platform called Agentforce. While we acknowledge the potential of CRM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
